PUYOU DE POUVOURVILLE Gérard, GILARD Martine, ELTCHANINOFF Hélène, IUNG Bernard, LEFÈVRE Thierry, SPAULDING Christian, DUMONTEIL Nicolas, MUTUON Pierre, ROUSSEL Christophe, CANDOLFI Pascal, GREEN Michelle, SHORE Judith
The clinical and cost-saving benefits of transcatheter aortic valve implantation (TAVI) over surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis who are at high or intermediate risk of surgical mortality are supported by a growing evidence base. The PARTNER 3 trial (Placement of AoRTic TraNscathetER Valve Trial) demonstrated clinical benefits with SAPIEN 3 TAVI compared with SAVR in selected patients at low risk of surgical mortality. This study uses PARTNER 3 outcomes in combination with a French national hospital claim database to inform a cost-utility model and examine the cost implications of TAVI over SAVR in a low-risk population.
GILARD, M., ELTCHANINOFF, H., IUNG, B., LEFÈVRE, T., SPAULDING, C., DUMONTEIL, N. … SHORE, J. (2022). Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France. Value in Health, 25(4), pp. 605-613.